Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06331156
Other study ID # 218485
Secondary ID 2022-000708-36
Status Recruiting
Phase Phase 3
First received
Last updated
Start date March 22, 2024
Est. completion date November 19, 2024

Study information

Verified date April 2024
Source GlaxoSmithKline
Contact US GSK Clinical Trials Call Center
Phone 877-379-3718
Email GSKClinicalSupportHD@gsk.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the immune response and safety of the inactivated poliovirus (IPV) vaccine when co-administered with the human rotavirus (HRV) porcine circovirus (PCV)-free vaccine in healthy Chinese infants 6-10 weeks of age at the time of study enrolment.


Recruitment information / eligibility

Status Recruiting
Enrollment 400
Est. completion date November 19, 2024
Est. primary completion date November 19, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Weeks to 10 Weeks
Eligibility Inclusion Criteria: - Participants' parent(s)/Legally Acceptable Representative(s) [LAR(s)], who, in the opinion of the investigator, can and will comply with the requirements of the protocol. - Written or witnessed/thumb printed informed consent obtained from the parent(s)/LAR(s) of the participant prior to performance of any study specific procedure. - Healthy participants as established by medical history and clinical examination before entering into the study. - A male or female of Chinese origin, between and including, 6 and 10 weeks (42-76 days) of age at the time of study enrolment. - Born after a gestation period of 36 to 42 weeks inclusive. Exclusion Criteria: Medical conditions - History of any reaction or hypersensitivity likely to be exacerbated by any component of the study interventions. - Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required). - Hypersensitivity to latex. - History of severe combined immunodeficiency. - History of seizures or progressive neurological disease. - Family history of congenital or hereditary immunodeficiency. - Uncorrected congenital malformation of the gastrointestinal tract that would predispose for intussusception (IS). - History of IS. - Major congenital defects, or serious chronic illness as assessed by the investigator. - Any contraindications to IPV. - Previous confirmed occurrence of rotavirus gastroenteritis (RVGE). - History of poliomyelitis. - Participants with confirmed or suspected Coronavirus Disease 2019 (COVID-19). Prior/Concomitant therapy - Use of any investigational or non-registered product other than the study interventions during the period beginning 30 days before the first dose of study interventions (Day -29 to Day 1), or planned use during the study period. - Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first dose and ending 30 days after the last dose of study interventions administration*, with the exception of the inactivated influenza vaccine, which is allowed at any time during the study and other licensed routine childhood vaccinations. *In case emergency mass vaccination for an unforeseen public health threat (e.g., a pandemic) is recommended and/or organized by public health authorities outside the routine immunization program, the time period described above can be reduced if, necessary for that vaccine, provided it is used according to the local governmental recommendations and that the Sponsor is notified accordingly. - Administration of long-acting immune-modifying drugs from birth or planned administration at any time during the study period. - Administration of immunoglobulins and/or any blood products or plasma derivatives from birth or planned administration during the study period. - Chronic administration of immunosuppressants or other immune-modifying drugs since birth. For corticosteroids, this will mean prednisone >=0.5 milligram/kilogram (kg)/day, or equivalent. Inhaled, intra-articular and topical steroids are allowed. - Previous vaccination against RV. - Previous vaccination against poliomyelitis. Prior/Concurrent clinical study experience - Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention. Other exclusions - Child in care.

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
HRV PCV-free
2 doses of HRV PCV-free vaccine are administered orally at Month 0.5 and Month 1.5 (Co-administration Group) and at Day 1 and Month 1 (Staggered Group), according to the immunization schedule for HRV vaccine licensed outside of China. PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.
IPV
3 doses of IPV vaccine are administered intramuscularly at Month 0.5, Month 1.5 and Month 2.5 (Co-administration Group and Staggered Group), according to the recommended schedule for vaccination against poliovirus in China.

Locations

Country Name City State
China GSK Investigational Site Chengdu Sichuan
China GSK Investigational Site Guang'an Sichuan
China GSK Investigational Site Neijiang Sichuan
China GSK Investigational Site Wenshan Yunnan
China GSK Investigational Site Wenshan

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of participants with seroconversion for anti-poliovirus types 1, 2 and 3 neutralizing antibody (Ab) Seroconversion for anti-poliovirus types 1, 2 and 3 neutralizing Ab is defined as: - Ab titer greater than or equal to (>=) 1:8 at 1 month after the 3 dose primary vaccination schedule of IPV in participants with Ab titer lower than (<) 1:8 at pre-vaccination,
- >= 4-fold increase in Ab titer at 1 month after the 3 dose primary vaccination schedule of IPV in participants with Ab titer >= 1:8 at pre-vaccination.
At 1 month post-Dose 3 of IPV (Month 3.5)
Secondary Anti-poliovirus types 1, 2 and 3 neutralizing Ab geometric mean titers (GMTs) At 1 month post-Dose 3 of IPV (Month 3.5)
Secondary Percentage of participants with anti-poliovirus types 1, 2 and 3 neutralizing Ab titers >=1:8 and >=1:64 At 1 month post-Dose 3 of IPV (Month 3.5)
Secondary Percentage of participants with seroconversion for anti-rotavirus (RV) immunoglobulin A (IgA) Ab Seroconversion for anti-RV IgA Ab is defined as: anti-RV IgA Ab concentration >= 20 unit per milliliter (U/mL) at 1 month post-Dose 2 of HRV PCV-free vaccine, in participants who were initially seronegative (i.e., with anti-RV IgA Ab concentration < 20 U/mL prior to the first dose of HRV PCV-free vaccine). At 1 month post-Dose 2 of HRV PCV-free (Month 2 for Staggered Group and Month 2.5 for Co-administration Group)
Secondary Anti-RV IgA Ab geometric mean concentrations (GMCs) At 1 month post-Dose 2 of HRV PCV-free (Month 2 for Staggered Group and Month 2.5 for Co-administration Group)
Secondary Percentage of participants with anti-RV IgA Ab concentrations >= 90 U/mL At 1 month post-Dose 2 of HRV PCV-free (Month 2 for Staggered Group and Month 2.5 for Co-administration Group)
Secondary Percentage of participants reporting solicited systemic events Solicited systemic events include fever, diarrhea, vomiting, irritability/fussiness, loss of appetite, cough/runny nose. Fever is defined as body temperature >= 37.5 degrees Celsius (°C) and the preferred location for measuring temperature is the axilla. Within 14 days after Dose 1 and Dose 2 of HRV PCV-free and IPV (Dose 1&2 administered at Day 1 & Month 1 (HRV PCV-free) and at Month 0.5 & Month 1.5 (IPV) for Staggered Group and at Month 0.5 & Month 1.5 (HRV PCV-free & IPV) for Co-administration Group)
Secondary Percentage of participants reporting unsolicited adverse events (AEs) Unsolicited AEs include any AE reported in addition to those solicited during the clinical study. Within 31 days after each dose of HRV PCV-free (HRV PCV-free administered at Day 1 and Month 1 for Staggered Group and at Month 0.5 and Month 1.5 for Co-administration group)
Secondary Percentage of participants reporting serious adverse events (SAEs) An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or in other situations that are considered serious per medical or scientific judgment. From the first dose of the study intervention (Day 1 for Staggered group and Month 0.5 for Co-administration group) up to study end (Month 3.5)
See also
  Status Clinical Trial Phase
Completed NCT01168401 - Bivalent Norovirus Vaccine Study Phase 1
Completed NCT02541695 - Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli N/A
Completed NCT02473887 - Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting Phase 1
Completed NCT01911143 - A Retrospective, Blinded Validation of a Host-response Based Diagnostics N/A
Not yet recruiting NCT01671137 - Probiotic for the Prevention of Functional Disorders in Childhood N/A
Completed NCT01917461 - Observational, Prospective Clinical Study to Evaluate Biomarkers as Indicators of Acute Bacterial or Viral Infections N/A
Withdrawn NCT00691275 - Efficacy Study of IV Fluids Only vs Ondansetron to Treat Dehydration N/A
Recruiting NCT06025695 - Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks Phase 3
Completed NCT04463082 - Non-invasive Assessment of the Current State of Hydration in Children by Ultrasound N/A
Completed NCT02497417 - A Multi-Site Clinical Evaluation of the ARIES Clostridium Difficile Assay in Symptomatic Patients N/A
Active, not recruiting NCT03000296 - Autologous Unselected Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease N/A
Completed NCT01225042 - The Effect of Probiotics on E. Coli Gastroenteritis N/A
Completed NCT01236066 - Impact of Rotavirus Vaccination on Hospitalisations for Rotavirus Gastroenteritis in Children Aged <5 Years in Australia N/A
Recruiting NCT00987519 - Viral Respiratory and Gastrointestinal Infections in Children Under 6 Years of Age N/A
Terminated NCT01357174 - ROTATEQ™ Post-Marketing Surveillance in the Philippines N/A
Completed NCT01033799 - Effect of the Consumption of a Fermented Milk on Common Infections in Shift-workers N/A
Recruiting NCT01363726 - Surveillance of Rotavirus Gastroenteritis in Children <5 Years N/A
Completed NCT00130832 - Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED) Phase 3
Terminated NCT02568189 - Utility of Ultrasound Assessment of the Inferior Vena Cava in Patients With Sepsis and Dehydration N/A
Terminated NCT02165813 - Oral Nitazoxanide in Acute Gastroenteritis in Australian Indigenous Children Phase 2/Phase 3